Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
401.08
+0.92 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
April 18, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
April 10, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Vertex to Announce First Quarter 2024 Financial Results on May 6
April 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading
December 13, 2023
Via
Investor Brand Network
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 03, 2024
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
Via
MarketBeat
Topics
ETFs
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
April 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease”
March 25, 2024
Via
AB Newswire
Exposures
Product Safety
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Via
MarketBeat
Exposures
Product Safety
bluebird bio: How to play LEAPS options for growth and income
February 27, 2024
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Via
MarketBeat
Exposures
Product Safety
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Vertex to Participate in Upcoming Investor Conferences
February 20, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
February 13, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
January 30, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
2 gene editing stocks to keep on your 2024 watchlist
January 23, 2024
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)
Via
MarketBeat
Exposures
Product Safety
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
January 17, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
January 16, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
January 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Will the Biotech sector sustain its momentum in 2024?
January 04, 2024
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.
Via
MarketBeat
Topics
ETFs
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High
January 03, 2024
Via
Investor Brand Network
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
CRISPR Therapeutics sets sights on gene-editing cures for disease
December 27, 2023
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for
Via
MarketBeat
Exposures
Product Safety
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
December 18, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
December 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
December 13, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.